EMBCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
Embecta Corp.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.21−0.06 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $363.36M
- P/E (TTM)
- 4.2
- Dividend yield
- 9.66%
Embecta Corp. revenue by segment
By business segment
By product or service
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pen Needles | $177.50M | $154.70M | $185.50M | $187.80M | $216.90M | $188.30M | $191.10M | $215.10M | $201.30M | $218.20M | $209.80M | – | 65.3% | -18.2% |
| Safety | $36.70M | $34.30M | $37.30M | $34.60M | $34.80M | $34.20M | $34.20M | $32.90M | $32.40M | $33.30M | $30.80M | – | 13.5% | +5.5% |
| Syringes | $36.60M | $26.30M | $30.70M | $32.30M | $35.10M | $28.80M | $28.40M | $33.70M | $31.70M | $30.00M | $30.80M | – | 13.5% | +4.3% |
| Other | $15.60M | $4.00M | $3.60M | $4.10M | $3.20M | $3.30M | $3.40M | – | $3.50M | $3.10M | $4.00M | – | 5.7% | +387.5% |
| Contract Manufacturing | $5.30M | $2.50M | $4.10M | $5.20M | $5.50M | $4.40M | $4.80M | $4.70M | $3.60M | $2.60M | $1.90M | – | 2.0% | -3.6% |
By region
| Revenue | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $150.90M | $126.40M | $130.30M | $122.00M | $135.30M | $123.80M | $120.20M | $118.70M | $128.90M | $139.60M | $128.70M | $130.10M | 55.5% | +11.5% |
| United States | $120.80M | $95.40M | $130.90M | $142.00M | $160.20M | $135.20M | $141.70M | $167.40M | $143.60M | $147.60M | $148.60M | $151.80M | 44.5% | -24.6% |
From the segment and revenue-disaggregation notes of Embecta's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.